Matrix Metalloproteinases -2 and -9, Vascular Endothelial Growth Factor, Basic Fibroblast Growth Factor and CD105-...

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Matrix metalloproteinases (MMPs) are crucial for extracellular matrix remodeling, playing roles in embryogenesis, wound healing, and tumor development.
• Aberrant expression of MMP-2 and MMP-9, alongside angiogenic markers such as vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and CD105-microvessel density (CD105-MVD), is a hallmark of tumor neoangiogenesis.
• Understanding the interplay of these markers in bladder cancer progression is vital for developing diagnostic and prognostic tools.

Purpose of the Study:

• To investigate the gene and protein expression levels of MMP-2, MMP-9, VEGF, bFGF, and CD105 in non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC) patients.
• To elucidate the relationships among these markers, their association with clinical features, and their role in bladder tumorigenesis and neoangiogenesis.
• To evaluate the diagnostic and prognostic significance of these markers in NMIBC and MIBC.

Main Methods:

• Gene expression analysis using real-time quantitative PCR in 70 NMIBC and 40 MIBC patients.
• Protein expression analysis via Western blotting and immunohistochemical staining.
• Scanning electron microscopy (SEM) to assess tumor vasculature and neoangiogenesis, alongside statistical analyses (ROC, Cox regression, Kaplan-Meier) to correlate marker expression with clinical data and patient survival.

Main Results:

• Elevated gene and protein expression of MMP-2, MMP-9, VEGF, bFGF, and CD105-MVD were observed with increasing tumor stage and grade.
• SEM studies revealed significant alterations in vascular architecture and increased vascular density in invasive tumors.
• Marker expression positively correlated with tumor stage, grade, size, type, and tobacco use history. ROC analysis confirmed their discriminatory ability, while survival analysis identified them as independent predictors of poor outcomes.

Conclusions:

• MMP-2, MMP-9, VEGF, bFGF, and CD105-MVD are significantly associated with bladder cancer progression and are indicative of poor prognosis.
• These markers play a role in bladder tumorigenesis through vascular angiogenesis.
• Further multi-center studies are warranted to validate their clinical utility in managing NMIBC and MIBC patients.